PE20021008A1 - Composiciones para vacuna antibacteriana - Google Patents
Composiciones para vacuna antibacterianaInfo
- Publication number
- PE20021008A1 PE20021008A1 PE2002000160A PE2002000160A PE20021008A1 PE 20021008 A1 PE20021008 A1 PE 20021008A1 PE 2002000160 A PE2002000160 A PE 2002000160A PE 2002000160 A PE2002000160 A PE 2002000160A PE 20021008 A1 PE20021008 A1 PE 20021008A1
- Authority
- PE
- Peru
- Prior art keywords
- bacteria
- gene
- mutation
- refers
- represented
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 241000894006 Bacteria Species 0.000 abstract 4
- 230000035772 mutation Effects 0.000 abstract 4
- 241000606752 Pasteurellaceae Species 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000002068 genetic effect Effects 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 230000001018 virulence Effects 0.000 abstract 2
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 abstract 1
- 241001293415 Mannheimia Species 0.000 abstract 1
- 241000606860 Pasteurella Species 0.000 abstract 1
- 241000606856 Pasteurella multocida Species 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229940051027 pasteurella multocida Drugs 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/809,665 US6790950B2 (en) | 1999-04-09 | 2001-03-15 | Anti-bacterial vaccine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021008A1 true PE20021008A1 (es) | 2002-11-13 |
Family
ID=25201919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000160A PE20021008A1 (es) | 2001-03-15 | 2002-02-27 | Composiciones para vacuna antibacteriana |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6790950B2 (enExample) |
| EP (1) | EP1368456B1 (enExample) |
| JP (2) | JP2005502315A (enExample) |
| AR (2) | AR035745A1 (enExample) |
| AT (1) | ATE500316T1 (enExample) |
| AU (1) | AU2002240033B2 (enExample) |
| CA (2) | CA2438315C (enExample) |
| CY (1) | CY1112014T1 (enExample) |
| DE (1) | DE60239318D1 (enExample) |
| DK (1) | DK1368456T3 (enExample) |
| ES (1) | ES2362041T3 (enExample) |
| MX (1) | MXPA03008296A (enExample) |
| NZ (1) | NZ528208A (enExample) |
| PE (1) | PE20021008A1 (enExample) |
| PT (1) | PT1368456E (enExample) |
| SI (1) | SI1368456T1 (enExample) |
| TW (4) | TWI335935B (enExample) |
| WO (1) | WO2002075507A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455323B1 (en) * | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| JP4892134B2 (ja) * | 1999-04-09 | 2012-03-07 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌ワクチン組成物 |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| US7449178B2 (en) * | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
| US7794734B2 (en) * | 2002-10-30 | 2010-09-14 | The Board Of Regents For Oklahoma State University | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever |
| GB0228691D0 (en) * | 2002-12-09 | 2003-01-15 | Imp College Innovations Ltd | Bacterial virulence genes |
| EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
| US8945589B2 (en) | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| US9107864B2 (en) * | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| EP2073829B1 (en) * | 2006-10-05 | 2012-06-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| AU2008299376B2 (en) | 2007-09-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | GAS57 mutant antigens and GAS57 antibodies |
| JP2011522796A (ja) | 2008-05-06 | 2011-08-04 | ニューヨーク ブラッド センター， インコーポレイテッド | 抗ウイルス細胞透過性ペプチド |
| CA2729818A1 (en) * | 2008-07-03 | 2010-01-07 | Biotechnology Research And Development Corporation | Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides |
| CA2774636C (en) | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9757445B2 (en) | 2013-11-01 | 2017-09-12 | Merial Inc. | Attenuated Pasteurella multocida vaccines and methods of making and use thereof |
| CN116593695B (zh) * | 2022-12-29 | 2025-08-05 | 重庆澳龙生物制品有限公司 | 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735801A (en) | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| US4877612A (en) | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
| DK166762B1 (da) | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
| US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
| CA1340522C (en) | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| PL170938B1 (pl) | 1991-03-05 | 1997-02-28 | Wellcome Found | Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL |
| US5840312A (en) | 1991-05-02 | 1998-11-24 | Institut Pasteur | Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein |
| WO1994011024A1 (en) | 1992-11-06 | 1994-05-26 | Regents Of The University Of Minnesota | Composition protective against p. multocida pasteurellosis infection |
| US5585277A (en) | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| WO1995020652A1 (de) | 1994-01-28 | 1995-08-03 | Medigene Gmbh | Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens |
| KR100445103B1 (ko) | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| BR9713195A (pt) * | 1996-09-06 | 1999-12-21 | Peter Ruhdal Jensen | Método de aperfeiçoamento da produção de biomassa ou de um produto desejado de uma célula. |
| US6673538B1 (en) * | 1997-07-25 | 2004-01-06 | The Trustees Of Boston University | Methods and compositions for designing vaccines |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| JP4892134B2 (ja) | 1999-04-09 | 2012-03-07 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌ワクチン組成物 |
| US6376211B1 (en) * | 1999-07-12 | 2002-04-23 | Xoma Technology Ltd. | Agents and methods for inhibiting F1/F0 ATPase |
| DE60124526D1 (de) * | 2000-04-27 | 2006-12-28 | Max Planck Gesellschaft | Methode zur identifizierung von helicobacter antigenen |
-
2001
- 2001-03-15 US US09/809,665 patent/US6790950B2/en not_active Expired - Lifetime
-
2002
- 2002-01-17 MX MXPA03008296A patent/MXPA03008296A/es active IP Right Grant
- 2002-01-17 CA CA2438315A patent/CA2438315C/en not_active Expired - Lifetime
- 2002-01-17 CA CA2852293A patent/CA2852293A1/en not_active Abandoned
- 2002-01-17 ES ES02705915T patent/ES2362041T3/es not_active Expired - Lifetime
- 2002-01-17 EP EP02705915A patent/EP1368456B1/en not_active Expired - Lifetime
- 2002-01-17 AU AU2002240033A patent/AU2002240033B2/en not_active Expired
- 2002-01-17 NZ NZ528208A patent/NZ528208A/en not_active IP Right Cessation
- 2002-01-17 DE DE60239318T patent/DE60239318D1/de not_active Expired - Lifetime
- 2002-01-17 DK DK02705915.3T patent/DK1368456T3/da active
- 2002-01-17 WO PCT/US2002/001971 patent/WO2002075507A2/en not_active Ceased
- 2002-01-17 JP JP2002574050A patent/JP2005502315A/ja active Pending
- 2002-01-17 AT AT02705915T patent/ATE500316T1/de active
- 2002-01-17 SI SI200230939T patent/SI1368456T1/sl unknown
- 2002-01-17 PT PT02705915T patent/PT1368456E/pt unknown
- 2002-02-07 AR ARP020100402A patent/AR035745A1/es not_active Application Discontinuation
- 2002-02-08 TW TW099122913A patent/TWI335935B/zh not_active IP Right Cessation
- 2002-02-08 TW TW099122912A patent/TWI335934B/zh not_active IP Right Cessation
- 2002-02-08 TW TW091102640A patent/TWI328035B/zh not_active IP Right Cessation
- 2002-02-08 TW TW097148939A patent/TWI334884B/zh not_active IP Right Cessation
- 2002-02-27 PE PE2002000160A patent/PE20021008A1/es not_active Application Discontinuation
-
2004
- 2004-05-26 US US10/854,299 patent/US7476391B2/en not_active Expired - Lifetime
-
2009
- 2009-05-22 AR ARP090101850A patent/AR071888A2/es unknown
-
2010
- 2010-11-04 JP JP2010247585A patent/JP2011097938A/ja active Pending
-
2011
- 2011-04-18 CY CY20111100401T patent/CY1112014T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002075507A2 (en) | 2002-09-26 |
| TW201040261A (en) | 2010-11-16 |
| ATE500316T1 (de) | 2011-03-15 |
| TWI334884B (en) | 2010-12-21 |
| NZ528208A (en) | 2008-04-30 |
| DE60239318D1 (de) | 2011-04-14 |
| CA2438315C (en) | 2014-09-02 |
| AR035745A1 (es) | 2004-07-07 |
| EP1368456B1 (en) | 2011-03-02 |
| MXPA03008296A (es) | 2007-05-28 |
| TWI328035B (en) | 2010-08-01 |
| JP2005502315A (ja) | 2005-01-27 |
| US20050003512A1 (en) | 2005-01-06 |
| AU2002240033B2 (en) | 2007-11-08 |
| PT1368456E (pt) | 2011-06-01 |
| SI1368456T1 (sl) | 2011-06-30 |
| CY1112014T1 (el) | 2015-11-04 |
| JP2011097938A (ja) | 2011-05-19 |
| US20040110268A1 (en) | 2004-06-10 |
| US6790950B2 (en) | 2004-09-14 |
| CA2438315A1 (en) | 2002-09-26 |
| ES2362041T3 (es) | 2011-06-27 |
| DK1368456T3 (da) | 2011-05-23 |
| WO2002075507B1 (en) | 2003-12-11 |
| AR071888A2 (es) | 2010-07-21 |
| TW200916577A (en) | 2009-04-16 |
| CA2852293A1 (en) | 2002-09-26 |
| TWI335935B (en) | 2011-01-11 |
| TW201040262A (en) | 2010-11-16 |
| WO2002075507A3 (en) | 2003-09-12 |
| TWI335934B (en) | 2011-01-11 |
| US7476391B2 (en) | 2009-01-13 |
| EP1368456A2 (en) | 2003-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021008A1 (es) | Composiciones para vacuna antibacteriana | |
| Merritt et al. | Motility and chemotaxis in Agrobacterium tumefaciens surface attachment and biofilm formation | |
| De Smet et al. | The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. | |
| Cornells et al. | ymoA, a Yersinia enterocolitica chromosomal gene modulating the expression of virulence functions | |
| Monstein et al. | Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori-associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis | |
| AR047150A1 (es) | Unidades de expresion p ef-tu y uso de las mismas en la regulacion de la transcripcion y expresion de genes | |
| Razin | Adherence of pathogenic mycoplasmas to host cells | |
| WO2000063364A3 (en) | Methods and compositions for inhibiting the function of polynucleotide sequences | |
| AR047151A1 (es) | Unidades de expresion p gro y uso de las mismas en la regulacion de la transcripcion y la expresion de genes | |
| AR029622A1 (es) | Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec | |
| Graf et al. | Nucleotide sequence of a Euglena gradlis chloroplast gene coding for the 16S rRNA: homologies to E. coli and Zea mays chloroplast 16S rRNA | |
| AR047152A1 (es) | Unidades de expresion psod y uso de las mismas en la regulacion de la transcripcion y la expresion de genes | |
| NZ593220A (en) | Immunostimulatory oligonucleotides | |
| US20220305141A1 (en) | Skeletal myoblast progenitor cell lineage specification by crispr/cas9-based transcriptional activators | |
| Martin et al. | Constitutive expression of erythromycin resistance mediated by the ermAM determinant of plasmid pAMβ1 results from deletion of 5′ leader peptide sequences | |
| Pougach et al. | CRISPR adaptive immunity systems of prokaryotes | |
| EP0939621A4 (en) | INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODE OXYNUCLEOTIDE | |
| US9402889B2 (en) | Live, oral vaccine for protection against Shigella dysenteriae serotype 1 | |
| BR0006915A (pt) | Sequências de nucleotìdios para o gene tal | |
| WO2021248016A3 (en) | Novel omni-59, 61, 67, 76, 79, 80, 81, and 82 crispr nucleases | |
| Beattie et al. | Transformation between Haemophilus influenzae and Haemophilus parainfluenzae | |
| AR025410A1 (es) | Metodo para preparar una bacteria s. thermophilus resistente al ataque de por lo menos un bacteriofago | |
| AR027762A1 (es) | Acidos nucleicos aislados de plasmido pmr2 de micromonospora rosaria y vectores preparados a partir de los mismos | |
| Shishido et al. | Correlation of enzyme-induced cleavage sites on negatively superhelical DNA between prokaryotic topoisomerase I and S1 nuclease | |
| Ashwath et al. | CRISPR and Antisense RNA Technology: Exploiting Nature’s Tool to Restrain Virulence in Tenacious Pathogens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |